Europe Acute Care Syndromic Testing Market - Analysis and Forecast, 2023-2033

2.1    Overview
2.2    Acute Care Syndromic Testing Workflow Analysis
2.3    Market Footprint and Growth Potential
2.4    Future Potential

3.1    Stakeholder’s Perspective (N=20)
         3.1.1    Physician’s Perception
         3.1.2    Payor’s Perception
         3.1.3    Investor’s Perception
3.2    Legal and Regulatory Framework of the Acute Care Syndromic Testing Market
         3.2.1    Regulatory Framework in North America
                     3.2.1.1    The U.S.
                     3.2.1.2    Canada
         3.2.2    Regulatory Framework in Europe
         3.2.3    Regulatory Framework in Asia-Pacific
                     3.2.3.1    Japan
                     3.2.3.2    China
                     3.2.3.3    India
                     3.2.3.4    South Korea
                     3.2.3.5    Australia
        3.2.4    Regulatory Framework in Latin America
                     3.2.4.1    Brazil
                    3.2.4.2    Mexico
        3.2.5    Regulatory Framework in Rest-of-the-World
                    3.2.5.1    U.A.E.
                    3.2.5.2    K.S.A.
3.3    Product Benchmarking

4.1    Overview
4.2    Impact Analysis
4.3    Market Drivers
         4.3.1    Faster Results Acquired with Syndromic Tests
         4.3.2    Increasing Incidence of Infectious Diseases
         4.3.3    Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
         4.3.4    Reduced Severe Adverse Effects from Pathogens
4.4    Market Challenges
         4.4.1    Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
         4.4.2    Lack of High-Complexity Testing Centres
4.5    Market Opportunities
         4.5.1    Quick Access to Treatment and Reduced Use of Antibiotics
         4.5.2    High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years

5.1    Overview
5.2    Europe
         5.2.1    Europe Acute Care Syndromic Testing Market, By End User
         5.2.2    Europe Acute Care Syndromic Testing Market, By Country
                     5.2.2.1    Germany
                     5.2.2.2    France
                     5.2.2.3    U.K.
                     5.2.2.4    Italy
                      5.2.2.5    Spain
                     5.2.2.6    Rest-of-Europe

6.1    Overview
6.2    Acute Care Syndromic Testing Ecosystem Active Players
6.3    Biocartis NV
         6.3.1    Company Overview
         6.3.2    Role of Biocartis NV in the Acute Care Syndromic Testing Market
         6.3.3    Financials
         6.3.4    Recent Developments
                  6.3.4.1    Business Strategies
         6.3.5    Analyst Perspective
6.4    bioMérieux SA (BioFire Diagnostics)
         6.4.1    Company Overview
         6.4.2    Role of bioMérieux SA (BioFire Diagnostics) in the Acute Care Syndromic Testing Market
         6.4.3    Financials
         6.4.4    Recent Developments
                  6.4.4.1    Business Strategies
         6.4.5    Analyst Perspective
6.5    DiaSorin S.p.A (Luminex Corporation)
         6.5.1    Company Overview
         6.5.2    Role of DiaSorin S.p.A (Luminex Corporation) in the Acute Care Syndromic Testing Market
         6.5.3    Financials
         6.5.4    Recent Developments
                  6.5.4.1    Corporate Strategies
                  6.5.4.2    Business Strategies
         6.5.5    Analyst Perspective
6.6    Eurofins Scientific (Eurofins Viracor)
         6.6.1    Company Overview
         6.6.2    Role of Eurofins Scientific (Eurofins Viracor) in the Acute Care Syndromic Testing Market
         6.6.3    Financials
         6.6.4    Recent Developments
                  6.6.4.1    Business Strategies
         6.6.5    Analyst Perspective
6.7    QIAGEN N.V.
         6.7.1    Company Overview
         6.7.2    Role of QIAGEN N.V. in the Acute Care Syndromic Testing Market
         6.7.3    Financials
         6.7.4    Recent Developments
                  6.7.4.1    Business Strategies
         6.7.5    Analyst Perspective
6.8    QuantuMDx Group Ltd.
         6.8.1    Company Overview
         6.8.2    Role of QuantuMDx Group Ltd. in the Acute Care Syndromic Testing Market
         6.8.3    Recent Developments
                  6.8.3.1    Corporate Strategies
                  6.8.3.2    Business Strategies
         6.8.4    Analyst Perspective
6.9    Siemens Healthineers AG
         6.9.1    Company Overview
         6.9.2    Role of Siemens Healthineers AG in the Acute Care Syndromic Testing Market
         6.9.3    Financials
         6.9.4    Analyst Perspective

Table 1:    Acute Care Syndromic Testing Product Mapping Analysis (by Disease Type)
Table 2:    Acute Care Syndromic Testing Market: Impact Analysis
Table 3:    Key Questions Answered in the Report
Table 4:    Product Benchmarking of Acute Care Syndromic Testing Panels
Table 5:    Likert Scale
Table 6:    Impact Analysis of Market Drivers
Table 7:    Impact Analysis of Market Challenges
Table 8:    Popular Assays and Their Turnaround Times
Table 9:    Acute Care Syndromic Testing Ecosystem Active Players

Figure 1:    Acute Care Syndromic Testing Market, $Billion, 2023 and 2033
Figure 2:    History of Known Pandemics
Figure 3:    Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
Figure 4:    Acute Care Syndromic Testing Market (by Disease Type), Share (%), 2022 and 2033
Figure 5:    Acute Care Syndromic Testing Market (by Target), Share (%), 2022 and 2033
Figure 6:    Share of Acute Care Syndromic Testing Market (by Region), 2022
Figure 7:    Share of Key Developments and Strategies, January 2020-June 2023
Figure 8:    Acute Care Syndromic Testing Market (by Company), Share (%), 2022
Figure 9:    Acute Care Syndromic Testing Market: Research Methodology
Figure 10:    Primary Research Methodology
Figure 11:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 12:    Top-Down Approach (Segment-Wise Analysis)
Figure 13:    Acute Care Syndromic Testing Workflow
Figure 14:    Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 15:    Physician's Perception on the Factors Affecting the Adoption of Acute Care Syndromic Testing
Figure 16:    Acute Care Syndromic Testing Market Dynamics
Figure 17:    Traditional Testing vs. Syndromic Testing
Figure 18:    Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
Figure 19:    Incidence of Common Infectious Diseases in Germany (Excluding COVID-19), 2020
Figure 20:    Incidence of Common Infectious Diseases in China, 2020
Figure 21:    History of Known Pandemics
Figure 22:    Examples of Cost Reductions
Figure 23:    Time of Diagnosis vs. Disease Effect
Figure 24:    Syndromic Panels Reimbursement Scenario in the U.S.
Figure 25:    Syndromic Panels Reimbursement Scenario in Mexico
Figure 26:    Reduction in Antibiotics Use with Syndromic Testing
Figure 27:    Increasing Synergistic Activities of the Acute Care Syndromic Testing Market, January 2021-June 2023 (Number of Partnerships, Collaborations and Agreements)
Figure 28:    Key Mergers and Acquisitions in the Acute Care Syndromic Testing Market
Figure 29:    Acute Care Syndromic Testing Market Snapshot (by Region)
Figure 30:    Acute Care Syndromic Testing Market (by Region), $Billion, 2022-2033
Figure 31:    Europe Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 32:    Europe Acute Care Syndromic Testing Market (by End User), $Billion, 2023-2033
Figure 33:    Europe Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
Figure 34:    Top 5 Most Common Infectious Diseases in Germany, 2020
Figure 35:    Germany Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 36:    France Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 37:    U.K. Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 38:    Italy Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 39:    Spain Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 40:    Rest-of-Europe Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 41:    Acute Care Syndromic Testing Market, Total Number of Companies Profiled
Figure 42:    Biocartis NV: Product Portfolio
Figure 43:    Biocartis NV: Overall Financials, $Million, 2020-2022
Figure 44:    Biocartis NV: R&D Expenditure, $Million, 2020-2022
Figure 45:    bioMérieux SA (BioFire Diagnostics): Product Portfolio
Figure 46:    bioMérieux SA (BioFire Diagnostics): Overall Financials, $Million, 2020-2022
Figure 47:    bioMérieux SA (BioFire Diagnostics): Revenue (by Segment), $Million, 2020-2022
Figure 48:    bioMérieux SA (BioFire Diagnostics): Revenue (by Region), $Million, 2020-2022
Figure 49:    bioMérieux SA (BioFire Diagnostics): R&D Expenditure, $Million, 2020-2022
Figure 50:    DiaSorin S.p.A (Luminex Corporation): Product Portfolio
Figure 51:    DiaSorin S.p.A (Luminex Corporation): Overall Financials, $Million, 2021 and 2022
Figure 52:    DiaSorin S.p.A (Luminex Corporation): Revenue (by Region), $Million, 2021 and 2022
Figure 53:    DiaSorin S.p.A (Luminex Corporation): R&D Expenditure, $Million, 2021 and 2022
Figure 54:    Eurofins Scientific (Eurofins Viracor): Product Portfolio
Figure 55:    Eurofins Scientific (Eurofins Viracor): Overall Financials, $Million, 2020-2022
Figure 56:    Eurofins Scientific (Eurofins Viracor): Revenue (by Segment), $Million, 2020-2022
Figure 57:    Eurofins Scientific (Eurofins Viracor): Revenue (by Region), $Million, 2020-2022
Figure 58:    QIAGEN N.V.: Product Portfolio
Figure 59:    QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 60:    QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 61:    QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 62:    QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
Figure 63:    QuantuMDx Group Ltd.: Product Portfolio
Figure 64:    Siemens Healthineers AG: Product Portfolio
Figure 65:    Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
Figure 66:    Siemens Healthineers AG: Revenue (by Segment), $Million, 2020-2022
Figure 67:    Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
Figure 68:    Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022